Note: This document contains side effect information about rasagiline. Some of the dosage forms listed on this page may not apply to the brand name Azilect.
Common side effects of Azilect include: dyskinesia. See below for a comprehensive list of adverse effects.
Applies to rasagiline: oral tablet
Along with its needed effects, rasagiline (the active ingredient contained in Azilect) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking rasagiline:
Some side effects of rasagiline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to rasagiline: oral tablet
When used as an adjunct to levodopa, the risk for developing posttreatment high blood pressure, combined with a significant increase from baseline was higher for rasagiline (the active ingredient contained in Azilect) (2%) compared to placebo (1%).
Clinical trial data suggest that orthostatic hypotension occurs more frequently during the first 2 months of rasagiline treatment and tends to decrease over time.
Postmarketing reports of elevated blood pressure, including rare incidents of hypertensive crisis associated with the ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking recommended doses of rasagiline.
Very common (10% or more): Orthostatic/postural hypotension
Common (1% to 10%): Angina pectoris, first degree AV block, hypertension, peripheral edema, peripheral vascular disorder
Uncommon (0.1% to 1%): Myocardial infarction
Postmarketing reports: Hypertensive crisis (after ingestion of unknown amounts of tyramine-rich foods)
Frequency not reported: Arrhythmia, blood pressure fluctuations, bradycardia, bundle branch block, cardiovascular disorder, complete AV block, heart arrest, pallor, palpitation, second degree AV block, thrombosis, vasodilatation, vascular disorder, ventricular arrhythmia, ventricular extrasystoles
Very common (10% or more): Dizziness, dyskinesia, headache
Common (1% to 10%): Ataxia, balance disorder, carpal tunnel syndrome, dystonia, paresthesia
Uncommon (0.1% to 1%): Cerebrovascular accident, somnolence
Frequency not reported: Hyperkinesias, myoclonus, nystagmus, speech disorder, withdrawal-emergent hyperpyrexia and confusion resembling neuroleptic malignant syndrome
Postmarketing reports: Serotonin syndrome
Dyskinesia or exacerbation of dyskinesia has been reported when rasagiline is used as an adjunct to levodopa. A dose reduction of levodopa may mitigate this effect.
Cases of patients treated with rasagiline and other dopaminergic medications falling asleep while engaged in activities of daily living including the operations of motor vehicles, have been reported and sometimes resulted in accidents. Some of these cases of somnolence have been reported more than 1 year after initiation of treatment.
The postmarketing reports of serotonin syndrome, associated with agitation, confusion, rigidity, pyrexia, and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline.
The symptom complex resembling neuroleptic malignant syndrome, with symptoms included elevated temperature, muscular rigidity, altered consciousness, and autonomic instability, has been reported with rapid dose reduction, and withdrawal of, or changes in, drugs that increase central dopaminergic tone.
Common (1% to 10%): Abnormal dreams, depression, hallucinations, insomnia, sleep disorder
Uncommon (0.1% to 1%): Confusion
Frequency not reported: Paranoid reactions, personality disorder
Postmarketing reports: Impulse control disorders, new or worsening mental status and behavioral changes including psychotic-like behavior
When studied as an adjunct to levodopa, the incidence of hallucinations was approximately 5% at a rasagiline dose of 0.5 mg per day, 4% at 1 mg per day, and 3% with placebo. Dose reduction or treatment discontinuation should be considered if hallucinations or psychotic-like behaviors develop.
Reduced impulse control or increased compulsive behaviors include intense urges to gamble, increased sexual urges, intense urges to spend money, and binge eating. Patients may not recognize these behaviors as abnormal. Dose reduction or treatment discontinuation should be considered if such urges develop.
Very common (10% or more): Accidental injury, fall
Common (1% to 10%): Fever, hernia, infection, malaise, otitis media, pain, sweating, vertigo
Frequency not reported: Chills, dysautonomia, prolonged immobilization
Common (1% to 10%): Alopecia, cellulitis, contact dermatitis, dermatitis, ecchymosis, rash
Uncommon (0.1% to 1%): Vesiculobullous rash
Frequency not reported: Abscesses, dry skin, gangrene, nail disorder, pruritus, psoriasis, skin ulcer, urticaria
Common (1% to 10%): Benign skin neoplasm, melanoma, skin carcinoma
Frequency not reported: Bladder carcinoma, breast neoplasm, cyst, Kaposi's sarcoma
Frequency not reported: Goiter, inappropriate antidiuretic hormone secretion
Very common (10% or more): Nausea
Common (1% to 10%): Abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastroenteritis, gingivitis, tooth disorder, vomiting
Frequency not reported: Colitis, dysphagia, eructation, esophagitis, fecal impaction, gastritis, gastrointestinal disorder, gastrointestinal hemorrhage, halitosis, intestinal obstruction, megacolon, mouth ulceration, periodontitis
Common (1% to 10%): Albuminuria, decreased libido, impotence, urinary urgency
Frequency not reported: Anuria, breast pain, dysmenorrhea, dysuria, nocturia, prostate-specific antigen increase, testis disorder, urogenital anomaly, vaginal hemorrhage
Common (1% to 10%): Hemorrhage, leucopenia
Uncommon (0.1% to 1%): Anemia
Frequency not reported: Eosinophilia, leukocytosis, megaloblastic anemia, thrombocytopenia
Frequency not reported: Abnormal liver function tests
Common (1% to 10%): Allergy
Common (1% to 10%): Flu syndrome, influenza, fungal infection
Frequency not reported: Sepsis, herpes simplex
Common (1% to 10%): Anorexia, decreased appetite, weight loss
Frequency not reported: Gout, hyperphosphatemia, hypokalemia, hypolipemia, increased lactic dehydrogenase, weight gain
Common (1% to 10%): Arthralgia, arthritis, back pain, joint disorder, musculoskeletal pain, myasthenia, neck pain, tendon disorder, tenosynovitis
Frequency not reported: Bursitis, leg cramps, myositis, rhabdomyolysis following fall, spinal stenosis, tendinous contracture
Common (1% to 10%): Abnormal vision, conjunctivitis
Frequency not reported: Blindness, diplopia, eye disorder, eye hemorrhage, glaucoma, vitreous disorder
Frequency not reported: Increased blood urea nitrogen, kidney pain
Common (1% to 10%): Asthma, cough, dyspnea, pharyngitis, rhinitis, upper respiratory infection
Frequency not reported: Allergic rhinitis, epistaxis, pneumothorax, pulmonary embolus
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Azilect